ASCO18: Day 4 update

Today at our booth

On the final day we had some great talks on PREOPANC-1, PRODIGE 7 and ASPECT. Although we’re sad to see ASCO 2018 draw to a close, it’s been a fantastic conference and we’re already looking forward to next year!

Remember to sign up for Oncology Central, or follow our Twitter updates @OncologyCentral.

Video highlights

Today’s news

Preoperative chemoradiotherapy improves survival time for patients with pancreatic cancer

A randomized Phase III trial has indicated that patients who received a combination of chemotherapy with radiation (chemoradiotherapy) before surgery for pancreatic cancer had a better disease-free survival than those who started their treatment with surgery. Preliminary findings of the trial demonstrate that chemoradiotherapy prior to surgery might be beneficial for patients with pancreatic cancer, with results showing that the 2-year survival rate was higher for those who received this treatment plan.

Read the full story.

High dose of Nexium® with aspirin reduces risk of developing esophageal cancer

Researchers have demonstrated that taking a high dose of esomeprazole (Nexium®) along with a low dose aspirin, for at least 7 years, can reduce the risk of develop a high-grade dyslplasia or esophageal cancer.

Full story here. 

PRODIGE 7 demonstrates that HIPEC may not be necessary for CRC patients

The PRODIGE 7 randomized has demonstrated that for advanced colorectal cancer patients, hyperthermic intra-peritoneal chemotherapy delivered to the abdomen during surgery, may not be necessary.

Discover further details here. 

Best of social media #ASCO18